Skip to main content
. 2021 Feb 19;16(2):e0247017. doi: 10.1371/journal.pone.0247017

Fig 2. Comparison of ratio of ADAMTS13 activity, ADAMTS13 antigen, and VWF antigen in ICU patient samples.

Fig 2

(A) Day 1 ADAMTS13 activity to antigen ratio in non-survivor septic (NS), survivor septic (S), non-septic, and healthy controls. (B) Day last ADAMTS13 activity to antigen ratio in non-survivor septic, survivor septic, and non-septic ICU. (C) Day 1 ratio of VWF AG:ADAMTS13[AC:AG] in non-survivor septic, survivor septic, non-septic, and healthy controls (D) Day last ratio of VWF AG:ADAMTS13 [AC:AG] in non-survivor septic, survivor septic, non-septic, and healthy controls. ADAMTS13 activity, ADAMTS13 antigen, and VWF antigen values normalized to pooled healthy control plasma and expressed as a percentage (mean±SD). Dunnett’s multiple comparisons test (one-way ANOVA). ****p≤0.0001, ***p≤0.001, **p≤0.01, *p≤0.05, and N.S. p>0.05.